{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"5.2","value":"1.7"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"23.7","value":"1.2"}]}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Tmax is defined as the time at which the Cmax occurs. It will be obtained from the Tmax parameter calculated by WinNonlin®. If there is no measurable Cmax in the subject's pharmacokinetic (PK) profile, then Tmax will be missing for that subject. Tmax will be reported in units of h.","dispersionType":"Full Range","groups":[{"description":"Participants received panobinostat 20 mg orally OD, three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.","id":"OG000","title":"Panobinostat"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in Pharmacokinetic Analysis (PAS) population, defined as all participants who provide at least one post-dose Pharmacokinetic (PK) plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Time to Peak Concentration (Tmax) of Panobinostat","type":"SECONDARY","unitOfMeasure":"Hours"}